Welcome to CSNpharm! For Research Use Only!
Home +1-708-781-1677

PLK

PLK

Cat. No. Product Name CAS No. Information
CSN15714 TAK-960 1137868-52-0 TAK-960 is an investigational orally bioavailable potent and selective PLK1 inhibitor IC5015 nM that has shown activity in several tumor cell lines including those that express multidrug-resistant protein 1 MDR1
CSN17496 TAK-960 HCl 2108449-45-0 TAK-960 hydrochloride is an investigational orally bioavailable potent and selective PLK1 inhibitor IC5015 nM that has shown activity in several tumor cell lines including those that express multidrug-resistant protein 1 MDR1
CSN16924 SBE13 HCl   1052532-15-6 SBE13 HCl is a potent and selective PLK1 inhibitor with IC50 of 02 nM while 875 nM and 66 M for PLK3 and PLK2 SBE 13 could also induce cell cycle arrest reduce cell proliferation with EC50 of 5-60 M and induce apoptosis in a broad range of human cancer cell lines
CSN16422 Ro 3280 1062243-51-9 RO3280 is a potent highly selective inhibitor of Polo-like kinase 1 PLK1 with IC50 of 3 nM
CSN18787 Rigosertib Sodium 592542-60-4 Rigosertib sodium is a non-ATP-competitive inhibitor of PLK1 with IC50 of 9 nM
CSN15803 Rigosertib Sodium (Random Configuration)   1225497-78-8 Rigosertib is a non-ATP-competitive inhibitor of PLK1 with IC50 of 9 nM in a cell-free assay It shows 30-fold greater selectivity against Plk2 and no activity to Plk3
CSN18349 Rigosertib 592542-59-1 Rigosertib is a non-ATP-competitive inhibitor of PLK1 with IC50 of 9 nM and shows 30-fold greater selectivity against PLK2 and no activity to PLK3
CSN18210 Poloxin 321688-88-4 Poloxin is a non-ATP competitive Polo-like Kinase 1 PLK1 inhibitor that targets the polo-box domain
CSN18009 Poloxime 17302-61-3 Poloxime is an analogue of thymoquinone which bind to the phosphoserinephosphothreonine recognition site of the polo-box domain of polo-like kinase 1
CSN16295 NMS-1286937 1034616-18-6 NMS-1286937 is an orally bioavailable small-molecule Polo-like kinase 1 PLK1 inhibitor IC502 nM with potential antineoplastic activity and no inhibition on PLK2 and PLK3
CSN16314 MLN0905 1228960-69-7 MLN0905 is a small-molecule and potent inhibitor of PLK1 with IC50 of 2 nM
CSN18151 LFM-A13 244240-24-2 LFM-A13 is a potent and selective inhibitor of Btk with IC50 of 172 M and also inhibits PLK3 with IC50 of 72 M
CSN16519 HMN-214 173529-46-9 HMN-214 is a potent PLK1 inhibitor an average IC50 of 012 M and a prodrug of HMN-176 which alters the cellular spatial orientation of Plk1
CSN19103 HMN-176 173529-10-7 HMN-176 is the active derivative of HMN-214 which can alter the cellular spatial orientation of Plk1
CSN12710 GW843682X 660868-91-7 GW843682X is a selective PLK1 and PLK3 inhibitor with IC50s of 22 nM PLK1 and 91 nM PLK3 and displays 100-fold selectivity over 30 other kinases tested including cdk1 and cdk2
CSN12716 GSK461364 929095-18-1 GSK461364 is a potent small molecule Polo-like kinase 1 PLK1 inhibitor with a Ki of 22 nM
CSN15736 CFI-400945 1338806-73-7 CFI400945 is a potent and selectiveorally bioavailable PLK4 inhibitor with an IC50 value of 28 14 nM have potential antineoplastic activity
CSN18037 Centrinone-B 1798871-31-4 Centrinone-B is a high affinity and selective PLK4 inhibitor Ki 059 nM
CSN17208 Centrinone 1798871-30-3 Centrinone is a selective and reversible inhibitor of polo-like kinase 4 Plk4 a serine-threonine protein kinase that initiates centriolecentrosome assembly
CSN12461 BI-2536 755038-02-9 BI-2536 is a potent Plk1 inhibitor with IC50 of 083 nM BI2536 shows 4- and 11-fold greater selectivity against Plk2 and Plk3 and also is a BRD4 inhibitor IC50 25 nM
CSN22785 Cyclapolin 9 40533-25-3
CSN12712 Volasertib 755038-65-4
CSN23160 TC-S 7005 1082739-92-1
<< PREV 1 NEXT >>